^
Association details:
| Biomarker: | EGFR L861Q |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + Tyvyt (sintilimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations
Excerpt:
...Patients with genetic testing (allowing PCR and NGS detection methods) confirmed uncommon mutations (EGFR G719X, L861Q, S768I, and 20ins et al.), patients can accept two or more types of EGFR rare co-mutation....
Trial ID:
Source:
Title:
Sintilimab in combination with anlotinib in non-small cell lung cancer patients with uncommon EGFR mutations: A phase II, single-arm, prospective study
Published date:
03/23/2022
Excerpt:
Among enrolled patients, twelve cases had EGFR Ex20ins and remaining nine cases had EGFR other mutations such as L861Q, G719A, and G709T. Patients harboring uncommon EGFR mutations exhibited a median progression-free survival of6.7 months (95% CI, 2.4, 11.0), and the 6-month PFS rate was 52.4%. Moreover, of the nineteen patients evaluable for efficacy, the objective response rate (ORR) was 36.8%(7/19), and the disease control rates (DCR) was 84.2% (16/19). Notably, patients carrying EGFR Ex20ins showed similar ORR/DCR and PFS with other mutation patterns(ORR: 36.4% [4/11] vs. 37.5% [3/8], p¼1.00; DCR: 90.9% [10/11] vs. 75.0% [6/8],p¼0.348, PFS: 4.3 vs. 7.1 months, p¼0.327). Combination of sintilimab and anlotinib demonstrated durable efficacy and good tolerability in NSCLC patients with uncommon EGFR mutations.
Trial ID:
